LAMP1 and chronic myelogenous leukemia, BCR-ABL1 positive: The comparison of NK cell response to K562 in healthy controls vs. TKI-treated CML patients did not show significant differences on CD107a expression in K562 stimulated NK cells when middle-aged healthy donors were compared with middle-aged or old CML patients (Figures 6B,C) supporting previous findings that TKI treatment is associated with immune system re-activation and restoration of NK cell immune surveillance in CML patients (40, 41).